Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far proved beyond the reach of medical science. But for the moment, that potential is far off, as both companies are working through clinical trials while subsisting solely on whatever revenue they can earn from their collaborations with other biopharmaceutical businesses.

With that in mind, is one of the pair more likely to succeed than the other? Let's evaluate which is the better gene-editing stock by examining each player's pipeline maturity, cash holdings, and target market size to find out.

The case for Rocket Pharmaceuticals is that it could be commercializing its first medicines in rare disease markets where there aren't any other options.

Continue reading

Source Fool.com